CAR T cells better than BiTEs
Author:
Affiliation:
1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and
2. Department of Pediatric Oncology, Johns Hopkins Hospital, Baltimore, MD
Publisher
American Society of Hematology
Subject
Hematology
Link
http://ashpublications.org/bloodadvances/article-pdf/5/2/602/1798461/advancesadv2020003554c.pdf
Reference52 articles.
1. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues;Gaudichon;Blood Rev,2019
2. Recent advances in managing acute lymphoblastic leukemia;DeAngelo;Am Soc Clin Oncol Educ Book,2020
3. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology;Brown;J Natl Compr Canc Netw,2020
4. CARs versus BiTEs: A comparison between T cell-redirection strategies for cancer treatment;Slaney;Cancer Discov,2018
5. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia;Topp;J Clin Oncol,2014
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin;Molecular Cancer Therapeutics;2024-04-19
2. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?;Clinical Hematology International;2024-03-13
3. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment;Blood Advances;2024-01-23
4. FCRL1 immunoregulation in B cell development and malignancy;Frontiers in Immunology;2023-09-25
5. Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells;Translational Oncology;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3